Abstract 1779P
Background
Salvage radiotherapy (SRT) is one of the cornerstone for treatment of biochemical relapse (BR) after radical prostatectomy (RP). One randomized controlled trial suggested that next generation imaging (NGI) may have a significant impact on patients management in this scenario. Nonetheless, how to best manage oligometastatic patients identified by PSMA PET imaging requires additional investigation. PSICHE (NCT05022914) is a prospective multicentric trial aimed to test a [68Ga]Ga- PSMA-11 PET/CT imaging tailored strategy.
Methods
Patients affected by biochemical relapse post RP (defined as PSA >0.2 ng/ml, <1 ng/ml) underwent [68Ga]Ga-PSMA-11 PET/CT imaging. After staging, management was performed according to a pre-defined algorithm. Observation and re-staging at further PSA progression were proposed to patients with negative PSMA and previous postoperative RT. Prostate bed SRT was proposed to all patients with a negative staging or positive imaging within prostate bed. Stereotactic body radiotherapy (SBRT) to all sites of disease was used for all patients with pelvic nodal recurrence (nodal disease < 2 cm under aortic bifurcation) or oligometastatic disease. Androgen deprivation therapy +/- androgen receptor targeted agent was provided in case of widespread metastatic disease. In the present analysis, we report early biochemical analysis focusing on complete biochemical response (PSA ≤0.2 ng/ml) and biochemical response (PSA ≤50% if compared to baseline value before treatment). Gastrointestinal (GI) or genitourinary (GU) toxicity was assessed according to CTCAE v 4.0.
Results
Overall, 110 patients were included in the current analysis. At 3 months after treatment, complete biochemical response and biochemical response were detected in 45.4% and 53.6% of patients, respectively. Seven patients had G1 GI toxicity, GU toxicity was reported in 30 patients (only 3 G2 adverse events, overall). No G>2 toxicity was reported.
Conclusions
A PSMA targeted treatment strategy led to promising results and was well tolerated within a prospective multicentric trial.
Clinical trial identification
NCT05022914.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1239P - NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
Presenter: Charles Swanton
Session: Poster session 14
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14